How much does a box of Jisandai (Bingtongsha) cost?

Epclusa (Epclusa) is an oral antiviral drug developed by Gilead Sciences for the treatment of chronic hepatitis C virus (HCV) infection of all genotypes. The main active ingredients of Jisanda (Bingtonsa) are sofosbuvir (Sofosbuvir) and velpatasvir (Velpatasvir), sofosbuvir is a nucleotide polymerase inhibitor, and velpatasvir is an NS5A inhibitor. The combination of the two can effectively inhibit the replication and spread of hepatitis C virus in the body.

Jisandai (Bingtonsha) is currently on the market in China and has been included in medical insurance. Patients can buy it domestically at a price of more than 3,000 yuan. Please consult the local hospital pharmacy for specific prices and medical insurance reimbursement. The cheaper ones abroad are generic drugs from India and Bangladesh, which cost around a few hundred yuan and have basically the same ingredients as domestic drugs.

Jisandai (Bingtonsha) is suitable for the treatment of chronic hepatitis C of all 6 genotypes, especially for patients with cirrhosis or those without cirrhosis who are ineffective with other drugs. For patients with decompensated cirrhosis, the combination of Bingtonsa and Ribavirin can further improve the efficacy.

Jisandai (Bingtonsha) is an oral drug, taken once a day, one tablet each time. It is recommended to take it at a fixed time. The treatment cycle is generally 12 weeks, but some severe cases may require longer treatment times. Before use, a professional doctor should evaluate the patient's specific situation and formulate a suitable treatment plan.

The clinical trial results of Jisanda (Bingtonsa) show that its cure rate for patients infected with HCV infection of all genotypes (SVR12, which means the virus cannot be detected 12 weeks after completion of treatment) exceeds 95%. Common side effects include headache, fatigue, nausea, etc., which are usually mild to moderate. For patients with severe liver function impairment, their liver function status should be closely monitored and treatment plans adjusted.

UseJisandai (Bingtongsha)During treatment, proton pump inhibitors and other drugs that may affect the absorption of velpatasvir should be avoided. At the same time, patients' viral load, liver function and other related indicators should be regularly monitored to ensure the safety and effectiveness of treatment. Jisandai (Bingtonsha) is not suitable for pregnant and lactating women. Before using this drug, you should inform your doctor of any medications you are taking or existing health problems.